secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123366
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q3 net loss $13.7M; cash $295.3M; Phase 3 Voyage on track for Q4 2024
-----------------------------------------------------------------------------

- Net loss $13.7M vs $17.9M a year ago; R&D expenses $17.2M (up $4.0M YoY) on MM120/MM402 programs.
- Cash and equivalents $295.3M as of Sep 30, 2024; expected to fund operations into 2027.
- Phase 3 Voyage study of MM120 ODT in GAD to start Q4 2024; 12-week topline data expected H1 2026.
- Phase 3 Panorama (GAD) and Phase 3 Emerge (MDD) studies on track to initiate in H1 2025.
- Completed Phase 1 study of MM402 (R(-)-MDMA) for Autism Spectrum Disorder in October 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024123366/0000950170-24-123366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024123366/mnmd-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer